X0202 SCHEDULE 13D/A 0002030245 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 04/27/2026 false 0001787518 67054R203 T3 Defense Inc.

575 Fifth Avenue, 14th Floor New York NY 10017

Menachem Shalom 212-791-4663 575 Fifth Avenue, 14th Floor New York NY 10017 0002030245 N Shalom Menachem OO N L3 14859080.00 0.00 14859080.00 0.00 14859080.00 N 25.42 IN This percentage is calculated based on (a) 51,270,525 shares of Common Stock issued and outstanding as of April 27, 2026 and 7,175,662 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person. Common Stock, $0.0001 par value per share T3 Defense Inc. 575 Fifth Avenue, 14th Floor New York NY 10017 This Amendment No. 1 to Statement on Schedule 13D filed on January 20, 2026 with the Securities and Exchange Commission with respect to the Common Stock, par value $0.0001 per share, of T3 Defense Inc., is being filed pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, to amend and supplement certain information set forth below in the items indicated. Only those items that are amended or supplemented are reported herein. All capitalized terms used in this Amendment No. 1 and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D. Except as amended and supplemented herein, the Schedule 13D, including the definitions of terms not otherwise defined herein, remains in full force and effect. The shares of Common Stock reported herein were acquired by the Reporting Person as follows: (i) On April 27, 2026, the Reporting Person exercised his right to purchase 67,009 shares of Common Stock and a 5-year warrant to purchase 2,357,303 shares of Common Stock from Esousa Group Holdings LLC pursuant to the terms of a Call Option Agreement dated January 13, 2026. (ii) On April 27, 2026, the Issuer changed the terms of the outstanding 3-month notes and 6-month issued in connection with the Amended and Restated Securities Purchase Agreement dated September 15, 2025 (the "Purchase Agreement") to provide the holders thereof with the right to convert the notes at an exercise price of $0.5124 per share. The Reporting Person converted the outstanding balance of $254,791 principal owed to him pursuant to the 3-month note received pursuant to the Purchase Agreement and the outstanding balance of $1,841,209 and accrued interest of $42,962 pursuant to the 6-month note received pursuant to the Purchase Agreement to an aggregate of 4,174,399 shares of Common Stock. The Reporting Person may be deemed to beneficially own an aggregate of 14,859,080 shares of Common Stock, representing approximately 25.4% of the outstanding shares of Common Stock of the Issuer. This amount consists of: (i) 7,683,418 shares of Common Stock; and (ii) 7,175,662 shares of Common Stock issuable upon exercise of warrants. The percentage calculation is based on (a) 51,270,525 shares of Common Stock outstanding as of April 27, 2026 and (b) 7,175,662 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person. The Reporting Person has sole voting and dispositive power with respect to 14,859,080 shares of Common Stock and shared voting and dispositive power with respect to 0 shares of Common Stock. Shalom Menachem /s/ Shalom Menachem 04/28/2026